The Neuroendocrine Cancer Foundation Podcast (previously known as the LACNETS Podcast) is a monthly series where we interview neuroendocrine tumor (NET) experts on various NET topics. Each expert will answer the top 10 FAQs in their area of expertise. Whether a listener is newly diagnosed, a longtime NET survivor, or a family member or loved one, the Neuroendocrine Cancer Foundation Podcast serves as a tool to help anyone better understand NET. The Neuroendocrine Cancer Foundation Podcast is also available on Apple Music, Spotify, Google Podcasts, and Amazon Music. Be sure to subscribe to our podcast to receive notifications when new episodes are released! 2026 2025 2024 2023 2022 2021 2026 2026 LISTEN LISTEN LISTEN 2025 2025 LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN 2024 2024 LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN 2023 2023 LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN 2022 2022 LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN 2021 2021 LISTEN LISTEN LISTEN LISTEN LISTEN

<< Back Pancreatic NET (PNET) Insulinoma upLIFT: Ersodetug in Insulinoma/Tumor Hyperinsulinism PRRT/RLT Trials Alpha PRRT with Pb-212 (all NET) Alpha PRRT with Ac-225 (GEP-NETs only) Alpha PRRT with Pb-212 VMT Alpha PRRT with RYZ401 in PRRT-naive Solid Tumors Expressing SSTRs Lu-177 DOTATATE + M3814 (Peposertib) (GEP-NETs) Lu-177 DOTATATE + Olaparib (GEP-NETs) Lu-177 DOTATATE + Triapine (GEP-NETs) Lu-177 DOTATATE + Cabozantanib (all NET) Lu-177 DOTATATE + Sunitinib in PNETs COMPOSE (GEP-NETS) ComPareNET Lu-177 vs CAPTEM in PNETs Lu-177 DOTATATE vs Everolimus in Lung NETs NETTER-P: Lutathera in Adolescent Patients Oral Treatment SWOG S2104: Adjuvant CAPTEM for High Risk pNET Belzutifan/MK-6482 in PNET + PPGL + VHL CDK4/6 Abemaciclib Other Trials Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas BRAVESST2: CRN09682 in SST2-Expressing NENs and Other Solid Tumors IL13Rα2 CAR T Cell Study for Solid Tumor Cancers SORENTO™: Subcutaneous Octreotide for GEP-NETs Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) SORENTO™: Subcutaneous Octreotide for GEP-NETs STELLAR-311: Zanzalintinib Versus Everolimus in pNET and epNET with Locally Advanced or Metastatic Neuroendocrine Tumors Survivin Long Peptide Vaccine (SurVaxM) in Metastatic NETs Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms

Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC << Back Ph I/II Trial of Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC CLINICALTRIALS.GOV IDENTIFIER: NCT03647163 Drug/Treatment: VSV-IFNβ-NIS and Pembrolizumab PHASE: I/II STATUS: Recruiting Sponsor: Vyriad, Inc. Collaborator: Mayo Clinic https://www.youtube.com/watch?v=Pw8oSIOt0og Dr. Heloisa Soares Discusses Systemic VSV-IFNβ-NIS and Pembrolizumab DESCRIPTION: Vyriad is sponsoring the safety run-in portion of this study is designed to identify the optimal dose of VSV-IFNβ-NIS in combination with pembrolizumab in patients with solid tumors and follows the 3+3 design. The expansion portion will use one-sample binomial designs to assess the efficacy of the combination in patients with refractory NSCLC or NEC. The optimal dose (RP2D) determined in the dose escalation portion of the trial will be used for the expansion portion. The study has been conducted with a dose of 1.7 × 1010 as the recommended phase II dose in an expansion cohort of 10 patients with NSCLC. However, current data suggests that VSV-IFNβ-NIS doses of up to 1.7 × 1011 is safe and likely more efficacious. Thus, this study will test a second VSV-IFNβ-NIS dose level, 1.0x1011 TCID50. A safety assessment will be carried out after 3 patients are enrolled. If this dose schedule is well tolerated and virus PK are not negatively impacted, both the NSCLC and NEC expansion cohorts will open using this dose schedule. If 2 of the first 3 patients or 2 of the first 6 patients experience a DLT, the dose will be de-escalated to 5 x 1010. The safety run-in/dose escalation portion of this study is expected to require a minimum of 3 patients and a maximum of 18 patients (6 patients per dose level). The expansion portion of this study is expected to require a minimum of 10 per cohort. The NSCLC and NEC patients enrolled at the identified optimal dose in the dose escalation cohort would be included in the dose expansion cohort if they are evaluable for the primary endpoint in the expansion portion (4 dose escalation patients at the optimal dose are expected to roll over to the expansion). Therefore, the overall sample size details will be a maximum of 40 patients. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT: Jennifer Boughton EMAIL: JBoughton@vyriad.com PHONE: 908-553-3135 Shruthi Naik, PhD EMAIL: snaik@vyriad.com PRINCIPAL INVESTIGATOR: Julian R. Molina, MD, PhD Mayo Clinic

Lung NET < Back to Topics Play Video Play Video 01:28:05 "Large Cell Neuroendocrine Carcinoma & Small Cell Lung Cancer" • Session B • LACNETS • Dec 10, 2024 This is a 2-session comprehensive guide to lung neuroendocrine cancers. Session A covers Typical Carcinoids and Atypical Carcinoids. Watch Session A here: https://youtu.be/owZRDf3ISM4 Session B covers Large Cell Neuroendocrine Carcinoma and Small Cell Lung Cancer. ABOUT AMAN CHAUHAN, M.D. Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer institute (NCI) that focused on designing clinical trials and clinical research projects. His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is national principal investigator on several investigator initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received a career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee. Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society. For more information, visit LACNETS.org. Play Video Play Video 01:33:36 "Typical Carcinoid & Atypical Carcinoid" • Session A • LACNETS Event • Dec 10, 2024 This is a 2-session comprehensive guide to lung neuroendocrine cancers. Session A covers Typical Carcinoids and Atypical Carcinoids. Session B covers Large Cell Neuroendocrine Carcinoma and Small Cell Lung Cancer. Watch Session B here: https://youtu.be/LxXdXMKpaCo ABOUT AMAN CHAUHAN, M.D. Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer institute (NCI) that focused on designing clinical trials and clinical research projects. His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is national principal investigator on several investigator initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received a career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee. Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society. For more information, visit LACNETS.org. Play Video Play Video 03:40 NET Patient Dorinda Shares her Journey - LACNETS Hear Dorinda's story Play Video Play Video 44:15 Episode 26 - What to Know About Lung NETs ABOUT THIS EPISODE What are lung NETs? What is DIPNECH? How is lung NET similar or different from lung cancer? Dr. Vineeth Sukrithan from Ohio State University Comprehensive Cancer Center gives a comprehensive overview of lung NET and DIPNECH, including the work-up and treatment options. He also discusses open clinical trials and exciting advances in lung NET research on the horizon. MEET DR. VINEETH K. SUKRITHAN Dr. Vineeth Sukrithan is a medical oncologist who specializes in the study and treatment of neuroendocrine cancer, thyroid cancer and adrenocortical cancer. He utilizes traditional chemotherapy, molecularly targeted oral medications, novel immunotherapy and peptide-receptor radiotherapies in the treatment of these unique cancers. As a comprehensive cancer center, the OSUCCC – James has unrivaled experience and expertise in the treatment of neuroendocrine, thyroid and adrenal tumors. Their world-renowned faculty are leaders in the study and treatments of these rare cancers, and as such, they are able to provide their patients with options beyond standard therapies that may not be available anywhere else. The strong focus on translational research at The James means that the treatment breakthroughs of tomorrow are being discovered in their laboratories today. Dr. Sukrithan is part of a tight-knit team of surgical oncologists, radiation oncologists and interventional radiologists who work together to provide cutting-edge care for our patients with neuroendocrine tumors. In addition to his clinical work, Dr. Sukrithan is a member of the Translational Therapeutics Program at the OSUCCC – James and the co-director of the Adrenal Tumor Clinic. He was recently selected to lead an externally funded effort through the International Thyroid Oncology Group to operationalize a multi-institutional registry database for patients with medullary thyroid cancer. Dr. Sukrithan also serves as an assistant professor in the Division of Medical Oncology at The Ohio State University and has completed postdoctoral fellowships in clinical research at Johns Hopkins University. His research has been published in numerous peer-reviewed journals, including Cancer Research, American Journal of Clinical Oncology and Clinical Lung Cancer. As every individual’s cancer is molecularly unique in countless ways, Dr. Sukrithan believes in tailoring therapies to the individual with the precision made available through cutting-edge scientific research. He feels it is a privilege to make a difference in the lives of patients as we work together to achieve a cancer-free world. TOP 10 QUESTIONS 1. What are lung NETs? Where are they located? 2. How are lung NETs found? What are the symptoms of a lung NET? 3. How is lung NETs different (or similar) to what is commonly referred to as “lung cancer”? 4. How is it different or similar to DIPNECH? Do all lung NET patients have DIPNECH and do all DIPNECH patients have lung NET? 5. How is lung NET similar or different from other types of NETs? What makes it unique? 6. What types of labs, scans, or testing is done to determine if someone has a lung NET and DIPNECH? What is the best type of scan for lung NETs? 7. How do you decide if the lung NET can be surgically removed? What type of surgeon would make that determination and when in their patient journey might they see a surgeon? 8. How are lung NETs treated medically (or nonsurgically)? How are the treatments different from other NETs? How are treatments sequenced? 9. How are lung NETs monitored? What types of blood work, tests and scans should be done and how often should they be done? 10. What advances in the field or clinical trials should we be aware of? What new advances or treatments in the pipeline for lung NETs are you most excited about? Play Video Play Video 01:28:16 LACNETS Webinar: "Update on Lung NETs" with Dr. Sukhmani Padda What types of lung NETs are there? How is lung NETs treated? Lung NET specialist Dr. Sukhmani Padda of Cedar-Sinai addresses these questions and gives an update on lung NETs. Lung NETs is a less common type of NET so we wanted to dedicate a webinar to this topic. *This webinar was recorded on August 25, 2022. Speaker: Sukhmani Padda, MD Lung NET Specialist, Cedars-Sinai Additional lung NETs resources can be found here: www.lacnets.org/lung-net-resources To learn more about LACNETS, visit www.LACNETS.org. Play Video Play Video 01:40:32 LACNETS Webinar: "Focus on Lung Carcinoid Tumors" with Dr. Robert Ramirez Join LACNETS and Lung NET expert Dr. Robert Ramirez of Vanderbilt University Medical Center, for his presentation and Q&A on, "Focus on Lung Carcinoid Tumors." Download the presentation slides from this webinar here: bit.ly/3l1BuyJ Speaker: Robert Ramirez, MD Associate Professor of Medicine Vanderbilt University Medical Center For more information on LACNETS, visit www.LACNETS.org. Play Video Play Video 01:17:15 "Systemic Therapy: GI, Lung, PNETS & Unknown Primary" 2020 LACNETS Virtual NET Conference Virtual 2020 Los Angeles Neuroendocrine Tumor Patient Education Conference Presented by LACNETS Presentations & Times: "Patient Story" (0:00 - 7:03) Eric, NET Patient "Systemic Therapy: GI NETs" (7:03 - 28:13) Dan Li, MD , Medical Oncology City of Hope "Systemic Therapy: Lung NETs" (28:13 - 52:08) Robert Ramirez, DO, FACP, Neuroendocrine & Thoracic Oncology Ochsner Medical Center "Systemic Therapy: PNETs and NETs of Unknown Primary" (52:08 - end of video) Andrew Hendifar, MD, Medical Oncology Cedars-Sinai Medical Center For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. < Back to Topics Next Topic >

Explore neuroendocrine tumor imaging resources like diagnostic scans, disease monitoring, staging, and imaging technologies used throughout NET care. Neuroendocrine Tumor Imaging Resources PODCAST Confused about scans? NET expert Dr. Gary Ulaner answers the top 10 questions about imaging for NETs. Dual board-certified in radiology and nuclear medicine, Dr. Ulaner explains different scans used in NET imaging including functional imaging scans such as Gallium-68 DOTATATE, Copper-64 DOTATATE, and FDG PET scans and anatomical scans such as MRI and CT scans. He addresses common questions about radiation safety, contrasts, and SUV. Listen Here EDUCATIONAL WEBINARS NET Imaging NET Imaging Play Video Share Whole Channel This Video Facebook Twitter Pinterest Tumblr Copy Link Link Copied Now Playing 3. Navigating Scans • Dr. Delphine Chen, Fred Hutch Cancer Center • Neuroendocrine Cancer Foundation 19:19 Play Video Now Playing 4. What Matters About Scans? • Nadine Mallak, MD • @NCFCancer 14:53 Play Video Now Playing "Understanding NET Scans" with Dr. Nadine Mallak • 2024 LACNETS NET Patient Conference 23:47 Play Video ADDITIONAL IMAGING RESOURCES Detectnet Patient Brochure by Curium Detectnet is used with a PET scan to help diagnose possible NETs A Guide to Understanding Neuroendocrine Tumors (NETs) and the Role of Imaging NANETS NET GUIDELINES 2017 (Joint with SNMMI) Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors

Alpha PRRT with Pb-212 VMT << Back Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors (212-Pb-VMT) IDENTIFIER ( ClinicalTrials.gov ) : NCT05636618 DRUG/TREATMENT : Alpha PRRT with 212Pb VMT PHASE : 1 / 2A STATUS : Recruiting SPONSOR : Perspective Therapeutics DESCRIPTION: https://www.youtube.com/watch?v=kOmdkMwoceQ June 2024: Dr. Aman Chauhan discusses the Alpha PRRT with Pb-212 VMT study. Perspective Therapeutics is sponsoring a phase 1 / 2A prospective, multi-center open-label dose escalation, dose expansion study of [212Pb]VMT01 in up to 52 adult subjects with unresectable or metastatic SSTR2-expressing neuroendocrine tumors (NETs) who have not received prior peptide receptor radionuclide therapy (PRRT). During phase 1, there is a dose escalation period testing up to 4 escalating radioactivity dose cohorts of up to 8 subjects (administered at approximately 8-week intervals) at the assigned cohort radioactivity dose. Phase 1 studies the side effects, safety, and dosimetry. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT : Markus Puhlmann, MD, MBA at Perspective Therapeutics EMAIL: mpuhlmann@perspectivetherapeutics.com PHONE: (319) 665-2150

Liver Directed Therapy < Back to Topics Play Video Play Video 20:09 7. Navigating Liver-Directed Therapy • Dr. Michael Soulen • Penn Medicine • 2026 NCF Conference In this session from the Neuroendocrine Cancer Foundation’s 2026 Virtual Annual Patient Conference, Dr. Michael Soulen, Director of Interventional Oncology at the University of Pennsylvania Abramson Cancer Center, presents **“Navigating Liver-Directed Therapy.”** Dr. Soulen explains why liver metastases are common and clinically important in neuroendocrine tumors, and how biopsy, tumor grade, Ki-67, serial imaging, and genetic sequencing can help guide treatment planning. He also reviews key liver-directed therapy options, including transarterial embolization, chemoembolization, radioembolization, ablation, and radiation-based approaches. This presentation discusses when liver-directed therapy may be considered, including liver-dominant disease, progression on somatostatin analogs, symptom control, bulky liver metastases, and treatment sequencing. Dr. Soulen also covers symptom relief, tumor shrinkage, and post-embolization syndrome. Learn more about the Neuroendocrine Cancer Foundation and access patient resources at www.NCF.net. For more information about this conference, visit https://www.ncf.net/events/2026conference This video is for educational purposes only and is not a substitute for professional medical advice. Please consult your medical team with questions about your individual care or treatment. #NeuroendocrineCancer #NeuroendocrineTumors #NETCancer #NETs #LiverMetastases #LiverDirectedTherapy #Embolization #Chemoembolization #Radioembolization #PRRT #CAPTEM #MichaelSoulen #PennMedicine #NCF #PatientConference #CancerEducation Play Video Play Video 12:56 3. Liver-Directed Therapy • Dr. Lindsay Thornton • 2025 NET Cancer Day Symposium Dr. Lindsay Thornton speaks about "Liver Directed Therapy" at the 2025 NET Cancer Day Symposium. The 2025 NET Cancer Day Symposium was a collaboration between the Neuroendocrine Cancer Foundation and the Sylvester Comprehensive Cancer Center, part of UHealth – University of Miami Health System, in Miami, Florida, on Sunday, November 9th. #netcancer #neuroendocrinecancer #netawareness #rarecancer #cancercommunity #advocacy #ncf #lacnets #AboveAndBeyondAward #netcancerday #cancereducation #netsupport Play Video Play Video 15:59 06. Liver-Directed Therapy: Killing Liver Tumors Without a Big Scar • Gregory Woodhead, MD, PhD Play Video Play Video 31:32 Episode 38: "NEN Treatments: Focus on Liver-Directed Therapies (Part 1) In this 2-part series, Dr. Osman Ahmed from University of Chicago covers liver-directed therapies for neuroendocrine neoplasms (NENs or neuroendocrine cancer). In this first episode, he outlines the types of liver-directed therapies and elaborates on ablative techniques including the newest technique, histotripsy. Listen to a frank discussion of how histotripsy works, when it might be used, and what its current limitations are. MEET DR. OSMAN AHMED Osman Ahmed, MD, is an expert vascular and interventional radiologist who diagnoses and treats a wide range of conditions. Using image-guided technology and small, sophisticated instruments, Dr. Ahmed performs minimally invasive procedures for acute and chronic deep vein thrombosis, benign prostatic hyperplasia, peripheral vascular disease, liver/bone/lung/kidney cancer, spinal fractures, uterine fibroids and more. He also implants inferior vena cava (IVC) filters, which prevent a blood clot from traveling around the body or creating a blockage. In addition to his clinical expertise, Dr. Ahmed researches novel treatment options that improve outcomes for patients. His research on liver cancer, IVC filters and venous diseases has been published in several high-impact, peer-reviewed journals, including the Journal of Vascular and Interventional Radiology, Radiology, Chest, Journal of American College of Radiology, and Journal of Surgical Oncology. Dr. Ahmed also believes in the importance of educating medical students, residents, fellowships and peers in order to enhance health care across the world. He has been invited to speak at a number of symposiums, practicums and national/international meetings about the newest advancements in interventional radiology. TOP TEN QUESTIONS ABOUT LIVER-DIRECTED THERAPY INCLUDING HISTOTRIPSY: 1. What is liver-directed therapy? How does it work? Is this considered “surgery”? What is a surgery and what is a “procedure?” 2. What are the types of liver-directed therapies used for neuroendocrine cancer? 3. Which neuroendocrine cancers are they used for and when are they used? How do you decide who is a good candidate and if it will be effective? 4. When are liver-directed therapies NOT used? Can someone who has had a Whipple undergo liver-directed therapy? 5. What is the ablation zone? What is a heat sink effect? 6. What is histotripsy? How does it work? 7. When is histotripsy used (tumor grade, type of tumor - PNET/lung NET, size, number of tumor, location)? Can they be used for liver tumors even if there are tumors outside the liver? 8. What are the limitations to histotripsy? 9. What happens to the liver tissue after ablation? What are the results or success rates of patients being treated? Can histotripsy “cure” NET? 10. How do you decide between the various types of liver-directed therapies? For more information, transcript and resources, visit https://www.lacnets.org/podcast/38. Play Video Play Video 01:35:06 "Evolving Management of NET Liver Metastases" Dr. Gagandeep Singh • 2024 #LACNETS Educational Event Join us to hear renowned liver and pancreas surgeon Dr. Gagandeep “Gaugs” Singh discuss the evolving algorithms in the management of NET liver metastases. Dr. Singh, Chief of Surgical Oncology at City of Hope® Cancer Center in Phoenix, asks the question of whether it is prudent to be aggressive surgically or if it is all about timing and strategy. For more information, visit LACNETS.org. Play Video Play Video 21:33 "Understanding Liver-Directed Therapy" with Dr. Soulen • 2024 #LACNETS Patient Conference 8) Understanding Liver-Directed Therapy • 2024 Neuroendocrine Tumor Patient Conference Our 2024 LACNETS Neuroendocrine Tumor Patient Conference is designed for neuroendocrine cancer (NET) patients and caregivers to deepen your understanding of NETs. Whether you are newly diagnosed or have been living with NET for many years, we encourage you to attend: - Learn from top NET experts from across North America on a range of topics relevant to the NET patient journey. - Topics include work-ups, scans, surgery, carcinoid crisis, liver-directed therapy, PRRT, systemic treatments, treatment sequencing, NET guidelines, and clinical trials. - Gain insight into NET decision-making through the NET tumor board panel discussion. - Hear stories from NET patients and caregivers. - Join virtually, where you can pause, rewind, or replay. - There is no cost to attend. This event is made possible by the generosity of donors and sponsors. #LACNETS #neuroendocrinecancer #clinicaltrials #lungcancer #NETcancer #Letstalkaboutnets For more information, visit LACNETS.org. Play Video Play Video 01:19:51 "Minimally Invasive Treatments for Neuroendocrine Liver Metastases" • Dr. Yilun Koethe • Dec 9, 2023 "Minimally Invasive Treatments for Neuroendocrine Liver Metastases" with Dr. Yilun Koethe, Interventional Radiologist, TRG Imaging. Learn more about minimally invasive liver directed therapies targeting liver metastases with interventional radiologist Dr. Koethe. She discusses ablations including the recently approved histotripsy and embolizations including bland, chemo and radioembolization. ~ Visit LACNETS.org for more information. Play Video Play Video 17:02 The Latest in Liver-Directed Therapy • Dr. Osmanuddin Ahmed • 2023 LACNETS Patient Conference Watch "The Latest in Liver-Directed Therapy" with Dr. Ahmed. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. For more information, visit LACNETS.org. Play Video Play Video 15:21 09. The Latest in Liver Directed Therapy + Histotripsy (Dr. Osman Ahmed) - 2022 LACNETS Conference International radiologist Dr. Osman "Os" Ahmed addresses the latest in liver-directed therapy and histotripsy for neuroendocrine cancer. Speaker: Osman Ahmed, MD International Radiologist, University of Chicago 2022 LACNETS NET Patient Conference Presented by LACNETS For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 01:05:05 LACNETS - "The Role of Interventional Radiology in NET" Dr. Steven Raman "The Role of Interventional Radiology in NET" Speaker: Steven Raman, M.D. Diagnostic and Interventional Radiology Specialist UCLA Medical Center Play Video Play Video 19:30 Interventional Radiology: Gabriel Lipshutz, MD - 2019 LA NET Conf Interventional Radiology: Gabriel Lipshutz, MD H. Gabriel Lipshutz, MD Interventional Radiology, Cedars-Sinai Medical Center 2019 Annual Los Angeles NET Patient Education Conference Saturday, June 8th www.LACNETS.org Play Video Play Video 01:20:02 Imaging & Role of IR (Liver-Directed Therapy) + PRRT - 2020 LACNETS Virtual NET Conference Virtual 2020 Los Angeles Neuroendocrine Tumor Patient Education Conference Presented by LACNETS Presentations & Times: "Patient Story" (0:00 - 6:06) Mary, NET Patient "Imaging & Role of IR (Liver-Directed Therapy)" (6:06 - 43:31) Michael C. Soulen, MD , Radiology Penn Medicine "Patient & Caregiver Story" (43:31 - 50:52) Shaunie, NET Patient; Heather, NET Caregiver "PRRT" (50:52 - end of video) Erik S. Mittra, MD, PhD, Diagnostic Radiology, Nuclear Medicine Oregon Health & Science University For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. Play Video Play Video 17:16 09. Liver-directed Therapy (Dr. Nutting) - 2021 LACNETS Virtual Conference 2021 Los Angeles Neuroendocrine Tumor Patient Education Virtual Conference Presented by LACNETS Presenter: Charles Nutting, DO Interventional Radiologist Endovascular Consultants of Colorado For more information, please visit www.LACNETS.org. @LACNETS (Facebook, Twitter, Instagram) Video produced by tvplive.com. < Back to Topics Next Topic >

Connect with the Neuroendocrine Cancer Foundation for vital resources and a supportive community tailored for NET patients and their caregivers. WATCH Podcast Blog Resources by Topic LATEST FROM NCF New Luncheon With The Experts with Dr. Aman Chauhan New Educational Event - "When Hormones Interfere With Quality of Life" with Dr. Del Rivero New Podcast - "NEN Treatments: Focus on Cabozantinib" with Dr. Vijayvergia New Educational Event - "Living With Neuroendocrine Cancer: The Caregiver/Co-Survivor Perspective" New Podcast - "Spotlight on Surgical Oncology" with Dr. Concors New - "Luncheon With The Experts" with Dr. Del Rivero Blog Pos t - "Continuing A 60-Year Legacy" "2025 Highlights in Neuroendocrine Cancer" New Blogpost - "The Email That Changed Everything" - Dusty Hurley New Educational Event - "The Latest on Immunotherapy for Neuroendocrine Cancer" with Dr. Aman Chauhan New Podcast Episode - "Spotlight on Pharmacists" with Amanda Cass, PharmD, BCPS, BCOP Watch "2025 Updates in NET" with Dr. Aman Chauhan Watch "The Latest in High-Grade Neuroendocrine Carcinoma (NEC)" with Dr. Aman Chauhan SIGN UP FOR EMAIL Stay up-to-date with neuroendocrine cancer news, educational information, monthly newsletters and ways to connect with other neuroendocrine cancer patients and caregivers. Make a Difference Donate today and help us provide support, and information on diagnosis, treatment options, research, and resources for NET patients and caregivers. DONATE UPCOMING NCF EVENTS Practical Tips in Managing Your Neuroendocrine Cancer Care Sep 29, 2026 Virtual Webinar Watch NET Cancer Day Symposium in Las Vegas, NV Nov 8, 2026 Virtual Webinar Register Visit our events page for more information >>> MAKE A DIFFERENCE Donate today and help us provide support, and information on diagnosis, treatment options, research, and resources for neuroendocrine cancer patients and caregivers. Donate LATEST ON CLINICAL TRIALS Clinical Trials News Play Video Play Video 06:31 Update on Cabozantinib Neuroendocrine Cancer Foundation Interview with Dr. Aman Chauhan • 2025 Clarification: The recent CABINET subgroup analysis presented at ESMO included thoracic NET patients (lung and thymic), with approximately 80% being lung NETs. Additionally, in the epNET cohort, about 20% of patients had lung NETs. Learn about one of the biggest breakthroughs in neuroendocrine tumor (NET) treatment: the FDA approval of Cabozantinib for metastatic NETs. In this in-depth interview, the Neuroendocrine Cancer Foundation’s Lisa Yen speaks with NET expert Dr. Aman Chauhan about the landmark CABINET clinical trial, new data from ESMO 2025, and what this means for patients with pancreatic NETs, extra-pancreatic NETs, lung NETs, and thymic NETs. Dr. Chauhan explains why Cabozantinib—a VEGF TKI targeted therapy—is transforming care for patients who often have limited treatment options, especially those with somatostatin receptor–negative lung NETs who may not qualify for somatostatin analogs (SSA) or PRRT. He also discusses promising results in higher-grade (G2–G3) well-differentiated NETs, an area with few effective treatment choices. ✔ What the CABINET trial revealed ✔ Why Cabozantinib is effective across multiple NET types ✔ How lung and thymic NET patients (thoracic NETs) benefited—~80% of the thoracic subgroup were lung NETs ✔ How this approval is changing clinical practice ✔ Introduction to Zanzalintinib (Zanza) — a next-generation VEGF TKI now entering phase 3 trials ✔ How to find NET clinical trials near you on ClinicalTrials.gov If you’re a patient, caregiver, or healthcare professional looking for new NET treatment options, this update provides essential insights into where the field is headed and how future drugs are being developed. 🔗 Search for NET clinical trials: https://www.ncf.net/clinical-trials Play Video Play Video 04:02 The Latest Advances in Neuroendocrine Cancer: An Update with Dr. Udhayvir Grewal • 2025 In this conversation, Dr. Udhayvir Grewal from the Winship Cancer Institute at Emory shares the newest developments in neuroendocrine cancer (NET/NEC) research, treatment, and clinical trials — offering clarity, progress updates, and hope for patients and caregivers in the NET community. 🔬 Key Highlights: - Alpha PRRT (Alpha Radioligand Therapy): New investigational treatments including Lead-212 Dotamtate, Lead-212 VMT-Alpha-NET, and Actinium-225 Dotatate (ACTION-1) are showing promising early results and may change the treatment landscape for NET patients. - New FDA-Approved Therapy for Pheochromocytoma & Paraganglioma: Belzutifan is now available for a subset of patients, supported by durable response data from the LITESPARK study. - Advances in High-Grade Neuroendocrine Carcinoma: Encouraging results are emerging from trials targeting DLL3, including obrixtamig, radioligand therapies, ADCs, and tri-specific drugs currently in development. 📍 Next Steps & Resources To explore active clinical trials and educational resources, visit: 🔗 NCF.net #NeuroendocrineCancer #NETCancer #NeuroendocrineTumor #CancerResearch #PRRT #ClinicalTrials #PatientEducation #NCF #NETUpdates #AlphaPRRT #DLL3 Play Video Play Video 06:26 The Latest in High-Grade Neuroendocrine Carcinoma (NEC): A Conversation with Dr. Chauhan • 2025 In this important update, Dr. Aman Chauhan shares the newest and most promising developments in treatment and research for high-grade neuroendocrine carcinoma (NEC) — a rare and aggressive form of neuroendocrine cancer. For decades, treatment options for NEC have been limited and outcomes have remained largely unchanged. Today, that reality is beginning to shift — and this conversation highlights the progress bringing renewed hope to patients and families. Highlights in This Discussion: - DLL3-targeted immunotherapy, including T-cell engagers such as tarlatamab and emerging therapies like Obrixtamig - Ongoing progress in clinical trials for high-grade NEC - Early success with radiopharmaceutical approaches targeting DLL3 - Exploration of oncolytic viruses, including the Seneca Valley Virus combined with ipilimumab (ipi) and nivolumab (nivo) - Advances in next-generation immunotherapy, including CAR-T and checkpoint combinations 📍 Want to Learn More? To explore active or upcoming clinical trials for NEC, visit the Neuroendocrine Cancer Foundation’s Clinical Trials Guide at NCF.net/clinical-trials #NeuroendocrineCancer #NEC #HighGradeNEC #ClinicalTrials #Immunotherapy #DLL3 #PatientEducation #NETCancer #NeuroendocrineTumor #CancerResearch #NCF Play Video Play Video 06:20 Dr. Jennifer Chan Shares 2025 Highlights & Future Directions in NET Research at the 2025 INCA Summit In this exclusive 2025 INCA Summit interview, Lisa Yen from the Neuroendocrine Cancer Foundation speaks with Dr. Jennifer Chan, President of NANETS and medical oncologist at Dana-Farber Cancer Institute, about the latest advances and future directions in neuroendocrine cancer research and treatment. Dr. Chan reflects on her 20-year journey in the field and highlights a pivotal year for neuroendocrine cancer care — including the FDA and EMA approvals of cabozantinib for both pancreatic and extrapancreatic NETs, and belzutifan for advanced pheochromocytomas and paragangliomas. She discusses how these breakthroughs are expanding treatment options and offering renewed hope to patients worldwide. Looking ahead, Dr. Chan shares her excitement about ongoing and upcoming clinical trials, including the COMPETE trial (PRRT vs. everolimus) and studies involving alpha-emitting PRRT agents, which may further transform clinical practice. 🎥 Highlights: Global collaboration through the International Neuroendocrine Cancer Alliance (INCA) Major new treatment approvals in 2025 (cabozantinib, belzutifan) Promising data from recent and emerging clinical trials (COMPETE, PRRT advances) A look toward the next wave of neuroendocrine cancer research 📍 Recorded live at the 2025 INCA Summit in Sofia, Bulgaria 👩⚕️ Guest: Dr. Jennifer Chan, President of NANETS 🎙️ Host: Lisa Yen, Neuroendocrine Cancer Foundation #NeuroendocrineCancer #INCA2025 #NANETS #Cabozantinib #Belzutifan #DanaFarber #OncologyResearch #PatientAdvocacy Play Video Play Video 05:29 Dr. Jennifer Chan & Dr. Del Rivero Discuss Advancing NET Research at the 2025 INCA Summit In this insightful conversation from the 2025 INCA Summit in Sofia, Bulgaria, leading neuroendocrine cancer experts Dr. Jennifer Chan (Dana-Farber Cancer Institute, USA) and Dr. Jaydira Del Rivero (National Cancer Institute, NIH) discuss the future of neuroendocrine tumor (NET) research, emphasizing the importance of clinical trials, patient engagement, and international collaboration. Dr. Del Rivero highlights the mission of INCA’s research committee—to align scientific priorities with patient needs, ensure greater patient participation in research, and develop better models and biomarkers for understanding and treating NETs. She explains the range of clinical research, from translational and molecular studies to natural history, prevention, and treatment trials, and how each contributes to improving diagnosis, therapy, and quality of life for patients. Dr. Chan underscores the vital role of patients as partners in research, helping shape meaningful endpoints and driving practice-changing discoveries like the CABINET trial, which recently led to new treatment approvals for neuroendocrine cancers. 🎥 Highlights: The mission of the INCA Research Committee Translational research and model development for NETs The value of biomarkers and molecular insights Understanding natural history studies and their role in cancer discovery Empowering patients as research partners Reflections on the impact of the CABINET study 📍 Recorded live at the 2025 International Neuroendocrine Cancer Alliance (INCA) Summit, Sofia, Bulgaria 👩⚕️ Speakers: Dr. Jennifer Chan & Dr. Jaydira Del Rivero #NeuroendocrineCancer #INCA2025 #ClinicalTrials #CancerResearch #PatientAdvocacy #DanaFarber #NIH #NANETS #CABINETTrial #OncologyResearch Play Video Play Video 05:30 Dr. Halfdanarson on ITM’s COMPETE Trial • 2025 ENETS • Neuroendocrine Cancer Foundation NANETS President Emeritus Dr. Thor Halfdanarson discussed the positive results from ITM’s Phase 3 COMPETE Trial at the 2025 ENETS Annual Medical and Scientific Conference in Krakow, Poland. The COMPETE trial was the first prospective, randomized phase 3 study comparing PRRT with an active treatment (everolimus or afinitor). For more information, visit https://www.ncf.net/clinical-trials. Play Video Play Video 05:27 Dr. Jennifer Chan Discusses Results of CABINET Trial (Cabozantinib) as Effective Treatment at ESMO24 Watch #LACNETS' exclusive view with incoming NANETS president Dr. Jennifer Chan at ESMO Congress 2024 (#ESMO24) in Barcelona, Spain, explaining the updated results of the CABINET trial evaluating Cabozantinib in Advanced Neuroendocrine Tumors. https://www.lacnets.org/post/positive-results-of-the-cabinet-trial-show-cabozantinib-as-a-new-effective-treatment-in-advanced-n Play Video Play Video 04:44 Dr. Aman Chauhan About the Most Exciting Progress in the Neuroendocrine Cancer Field @ NANETS Miami In this exclusive interview at NANETS Regional in Miami, NET expert Dr. Aman Chauhan from Sylvester Comprehensive Cancer Center shares the recent advances he's most excited about in the neuroendocrine cancer field. @SylvesterCancer @AmanChauhanMD @CarcinoidNETs @HealingNET1 @netcancerday @CureNETs @PheoPara #NETsMiami NETTER-2 Trial Supports Lutathera® as 1st Line Treatment >>> Dr. Jennifer Chan Announces the CABINET Trial Data on Cabozantinib >>> Clinical Trials Guide WATCH 550+ Videos on Various Topics 2025 NET Cancer Day Symposium LISTEN Hear Experts Answer Top 10 Questions on Each Topic "Against the Tide: The Mary Donlevy Story" TAKE ACTION Learn How You Can Share Your Story RECENT EDUCATIONAL EVENTS FOR PATIENTS Play Video Play Video 01:34:59 Just Diagnosed With Neuroendocrine Cancer? What to Know and Understand • 2026 NCF Event • Apr 23, 26 ABOUT Being newly diagnosed with neuroendocrine cancer (NETs) can feel overwhelming. Many patients find themselves asking, “What exactly is neuroendocrine cancer, and how is it different from other cancers?” This webinar is designed to bring clarity, reassurance, and guidance during one of the most confusing stages of the NET journey. Join Dr. Osama MoSalem, medical oncologist at St. Luke’s in Kansas City, for a clear and compassionate overview of what every newly diagnosed NET patient should know. Dr. MoSalem explains what neuroendocrine cancer is, why it behaves differently from more common cancers, and how its unique features influence diagnosis and treatment. This session walks you through the most important early concepts, including: - Grade and stage: what they mean and why they matter - Key tests and scans used at diagnosis - Treatment pathways, including when to consider surgery, medications, targeted therapies, radioligand therapy, or clinical trials - Essential questions to ask your care team - Practical first steps to help you feel more prepared and empowered Whether you’re newly diagnosed, supporting a loved one, or simply trying to better understand this disease, this webinar provides a solid foundation to help you make informed decisions with greater clarity and confidence. Visit the event page at https://www.ncf.net/events/apr2026 Play Video Play Video 01:33:06 Novel Targeted Therapies in Neuroendocrine Cancers • 2026 NCF Event • Mar 9, 2026 Some Topics Covered: Neuroendocrine, NET, NEC, High-grade Clinical trials, PRRT, RLT, Antibody Drug Conjugate (ADC), DLL3 ABOUT Learn from a discussion of targeted therapies in neuroendocrine cancer, one of the fastest-growing areas of NET treatment. Unlike traditional chemotherapy, targeted therapies focus on specific pathways or features of cancer cells. Understanding how these treatments work can help patients feel more confident and informed when discussing options with their care team. In this session, Dr. Rohit Thummalapalli, medical oncologist at Memorial Sloan Kettering Cancer Center, explores novel, innovative targeted treatments used or being studied in NETs, such as DLL3 and antibody–drug conjugates (ADCs). Dr. Thummalapalli will explain what these therapies are, how they work, and why they are becoming increasingly important in NET care. Whether you’re newly diagnosed or considering later-line treatments, this webinar will help you better understand the evolving landscape of targeted therapy and what it may mean for your care. Visit the event page at https://www.ncf.net/events/mar2026 Play Video Play Video 01:29:26 The Latest in Neuroendocrine Cancer Clinical Trials • 2026 NCF Event • Feb 20, 2026 Topics Covered: Neuroendocrine, NET, clinical trials, PRRT, RLT, neoadjuvant trials, adjuvant trials, metastatic NET, symptom control ABOUT Join us for an overview of the latest clinical trials in neuroendocrine cancer with Dr. Heloisa Soares, a medical oncologist and physician-scientist at the Huntsman Cancer Institute (HCI) in Salt Lake City. Dr. Soares will walk through key neuroendocrine cancer clinical trials including what they are studying, what makes them exciting, and how they may shape future treatment options. She will also explain why clinical trials matter, how they benefit patients, and what to consider when exploring whether a trial might be right for you. Whether you’re a patient, caregiver, or simply trying to stay informed, this webinar will provide clear, practical insights to help you better understand emerging research and what it means for the neuroendocrine cancer community. The presentation focuses on current NET clinical trials. For information on NEC clinical trials, go to our high grade resources page: https://www.ncf.net/high-grade-nen-resources. Visit the event page at https://www.ncf.net/events/feb2026 Play Video Play Video 01:31:30 The Latest on Immunotherapy for Neuroendocrine Cancer • 2025 NCF Event • Dec 11, 2025 Immunotherapy is an exciting and rapidly advancing area in the treatment of neuroendocrine cancer. Join Dr. Aman Chauhan, Medical Oncologist at the University of Miami Sylvester Cancer Center, as he discusses the latest developments in immunotherapy for neuroendocrine cancer. This webinar will cover current standard-of-care treatments as well as cutting-edge clinical trials involving DLL3-targeted therapies, oncolytic viruses, CAR T-cell therapy, and combination approaches. Whether you’re newly diagnosed or exploring new treatment options, this session will help you better understand the evolving landscape of immunotherapy in neuroendocrine cancer. Aman Chauhan, MD Medical Oncologist University of Miami Sylvester Cancer Center Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer Institute (NCI) that focused on designing clinical trials and clinical research projects. His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is the national principal investigator on several investigator-initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received a career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee. Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society. Visit https://www.ncf.net/events/dec2025 for more information. Play Video Play Video 01:27:39 Understanding Alpha & The Evolving PRRT Landscape • Dr. Grewal • 2025 NCF Event • September 22, 2025 The field of PRRT (Peptide Receptor Radionuclide Therapy) is evolving rapidly, and patients are hearing more about new developments like alpha therapies, the recent NETTER-2 and COMPETE trial results, and other advances. Join medical oncologist Dr. Udhayvir Singh Grewal from the Winship Cancer Institute of Emory University as he breaks down what these changes mean for people living with neuroendocrine cancer. This webinar will help patients and caregivers make sense of emerging research and therapies—and what they may mean for the future of NET treatment. For more information, visit https://www.ncf.net/events/sep2025. Play Video Play Video 01:25:23 Nutrition & Diet Considerations for NETs • 2025 NCF Event • August 26, 2025 Nutrition can play a key role in living well with neuroendocrine cancer (neuroendocrine tumors or NETs). Join NET dietitian Meghan Laszlo for an informative session on nutrition and diet considerations for people living with neuroendocrine cancer. She will cover key topics including the use of pancreatic enzymes, managing hyperglycemia, navigating special diets, and understanding supplements. Whether you're newly diagnosed or further along in your journey, this webinar offers practical guidance to help you make informed nutrition choices that support your health and quality of life. For more information, visit ncf.net. Play Video Play Video 01:16:25 Living with NET: The Patient Perspective • 2025 NCF Event • July 10, 2025 Patients share their experiences on topics, including decision-making, coping strategies, lessons learned, challenges, and navigating relationships while living with neuroendocrine cancer. Hear about their personal journeys—filled with resilience, realities, and hope, that offer powerful insight into what it's like living with neuroendocrine cancer. Visit NCF.net/July2025 for more information. Play Video Play Video 01:33:27 "Evolving Management of Carcinoid Heart Disease" • Prashanth Venkatesh, MD, FACC • April 29, 2025 Learn from Cardiologist and Congenital Heart Disease Specialist, Dr. Prashanth Venkatesh from Cedars-Sinai Smidt Heart Institute in a virtual educational event on carcinoid heart disease. Dr. Venkatesh demystifies the topic and shares the latest developments in its diagnosis and treatment, including a novel minimally invasive approach to replace heart valves damaged by carcinoid heart disease. For more information and resources, visit NCF.net. LATEST PODCAST EPISODES LISTEN LISTEN LISTEN LISTEN RESOURCES & INFORMATION FOR YOU Meetings Register for the upcoming educational webinars and programs Support Groups Learn about the NET patient and caregiver support groups Podcast A podcast series where neuroendocrine cancer experts answer the top 10 FAQs on various topics Resources Check our resource navigation guide which covers various topics from treatment options to wellness NETCONNECT A peer support system that connects newly-diagnosed patients with mentors Newly Diagnosed Newly-diagnosed NET patients can begin exploring here for resources and support NET VITALS A tool for patients and healthcare professionals to share vital information about a patient’s neuroendocrine cancer Clinical Trials Explore open clinical trials here Blog Read about various NET topics, inspiring survival stories, and tips to live fully and richly with cancer Patient & Caregiver Stories Find inspiration and hope from NET patient and caregiver stories Spanish Resources Explore Spanish-language resources for NET patients and caregivers Health Coaching Learn how you can receive one-on-one coaching sessions available to NET patients and caregivers ABOUT THE NEUROENDOCRINE CANCER FOUNDATION Why Our Work Matters The Neuroendocrine Cancer Foundation (NCF) exists to ensure no one faces neuroendocrine cancer alone. We support patients, caregivers, and clinicians through education, connection, and compassionate resources. Educate Educational Events Luncheon With The Experts w/Live Q&A In-Person Patient & Caregiver Events Online Video Library (YouTube & Web) Resource Library on 25 Topics Podcast Spanish Resources Support Support Line Resources for Newly Diagnosed Support Groups Health & Wellness Retreat Wellness Coaching Connect NETCONNECT Peer-to-Peer Program NET VITALS NET INTRO Inform Clinical Trials Guide Amplify Patient Voice Neuroendocrine cancer (also known as NET, neuroendocrine tumor, neuroendocrine neoplasm, carcinoid, or neuroendocrine carcinoma) is a rare/uncommon and complex disease. 8 in 100,000 people in the U.S. are diagnosed each year Symptoms vary widely and are often misunderstood Diagnosis can take several years Many patients do not meet someone else living with neuroendocrine cancer until they find NCF Patients often struggle to find specialists, up-to-date treatment guidance, and emotional support. NCF fills those gaps by offering what patients need most: credible education, expert access, and a community that understands. NCF provides these life-changing resources — ensuring patients and families receive guidance when it matters most. I was officially diagnosed on June 29, 2022. I didn’t even know NETs existed. And today...less than a month later, I’ve learned so much thanks to the incredible resources that exist as a result of the beautiful NETs community. The resources available, especially the videos from the (Neuroendocrine Cancer Foundation) and the NET VITALS document, are so life-giving and helpful for the newly diagnosed. The Neuroendocrine Cancer Foundation contributes so much useful information to the NET community. — NET Patient Leave A Review

< Back to the supporters page ABOUT IPSEN Ipsen is a global biopharmaceutical company focused on innovation and specialty care. At Ipsen, we develop and commercialize medicines in three key therapeutic areas – Oncology, Neuroscience and Rare Disease. Our oncology work focuses on solid tumors and some of the hardest-to-treat cancers. We have a growing portfolio of therapies aimed at improving the lives of patients with gastrointestinal and pancreatic neuroendocrine tumors, carcinoid syndrome, and pancreatic cancer. Every day, our more than 5,700 employees worldwide, including over 600 in North America, work diligently to improve the lives of patients around the world. For more information please visit www.ipsenus.com . PATIENT BROCHURES Download the Patient Brochure Click here to download the injection prep brochure OTHER RESOURCES Click here to download the SOMATULINE® DEPOTprescribing information packet. SOMATULINE® DEPOT Website IPSEN Cares Website Contact an Ipsen Representative Alice Donnelly Manager, Portfolio Communications Email: alice.donnelly@ipsen.com Phone: (973) 936-4697 This information is for educational purposes only and does not substitute for medical advice or constitute an endorsement by the Neuroendocrine Cancer Foundation. Talk to your medical team about your individual care and treatment. Confirm Your Visit to the Novartis Virtual Booth! First name Last name Email Submit << Previous Next >>

<< Back Gastrointestinal (GI) NETs PRRT/RLT Trials Alpha PRRT with Pb-212 (all NET) Alpha PRRT with Ac-225 (GEP-NETs only) Alpha PRRT with Pb-212 VMT Alpha PRRT with RYZ401 in PRRT-naive Solid Tumors Expressing SSTRs Lu-177 DOTATATE + M3814 (Peposertib) (GEP-NETs) Lu-177 DOTATATE + Olaparib (GEP-NETs) Lu-177 DOTATATE + Triapine (GEP-NETs) Lu-177 DOTATATE + Cabozantanib (all NET) COMPOSE (GEP-NETS) NETTER-P: Lutathera in Adolescent Patients NET RETREAT of Lu-177 Retreatment vs Everolimus in Midgut NET Oral Treatment CDK4/6 Abemaciclib SSA Treatments BRAVESST2: CRN09682 in SST2-Expressing NENs and Other Solid Tumors Paltusotine in Carcinoid Syndrome SORENTO™: Subcutaneous Octreotide for GEP-NETs Other Trials Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas CHM-2101 CAR-T cell for GI Cancers IL13Rα2 CAR T Cell Study for Solid Tumor Cancers Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) STELLAR-311: Zanzalintinib Versus Everolimus in pNET and epNET with Locally Advanced or Metastatic Neuroendocrine Tumors Survivin Long Peptide Vaccine (SurVaxM) in Metastatic NETs Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms

Join our mission to support the neuroendocrine cancer community. Your contribution helps raise awareness and bring hope to patients today. Make a Difference: Donate to the Neuroendocrine Cancer Foundation Your donation helps us provide a community of support and education for those affected by neuroendocrine cancer and to advocate for all people impacted by this rare disease. Special donations may be made in honor of or in memory of a loved one. DONATE ONLINE The Neuroendocrine Cancer Foundation is a 501(c)(3) non-profit corporation, Tax ID #20-0062062. All donations are tax-deductible as allowed by law. The Neuroendocrine Cancer Foundation may show up as LACNETS or GeneratePossibility (our former names) when searching by our Tax ID. We accept checks made to the Neuroendocrine Cancer Foundation or LACNETS. MORE WAYS TO GIVE BY CHECK To donate by check, please make checks payable to "Neuroendocrine Cancer Foundation" and mail to: Neuroendocrine Cancer Foundation PO Box 370466 Denver, CO 80237 DONOR-ADVISED FUND A donor-advised fund allows you to maximize your tax benefits while supporting the Neuroendocrine Cancer Foundation. Initiate gift through DAF Direct STOCK OR SECURITIES Make a gift of publicly-traded securities to the Neuroendocrine Cancer Foundation and save on income tax and capital gains tax. Contact info@ncf.net for instructions LEGACY GIFT The Neureondocrine Cancer Foundation can be included as a beneficiary of your will, trust, retirement plan, or life insurance plan. Contact us at info@ncf.net FACEBOOK FUNDRAISER Personal Facebook fundraisers can support the Neuroedocrine Cancer Foundation, while raising awareness of NET. Start a Facebook fundraiser MATCHING GIFTS A matching gift from your employer may double or triple your donation. See if your employer will match your donation. DONATE YOUR CAR Vehicle donations are eligible to be claimed as deductions for federal income tax purposes. Contact info@ncf.net There are many ways to give. Contact Kavya Velagapudi, Executive Director, at Kavya@NCF.net to discuss your idea.

Learn more about the NET experts presenting on various topics during the 2023 LACNETS Neuroendocrine Tumor Patient Conference. 2023 LACNETS + PPA + NCI Patient Conference Speakers SURGERY 101 FOR NETS JAMES HOWE, MD Professor of Surgery Director, Surgical Oncology and Endocrine Surgery Roy J. and Lucille A. Carver University of Iowa College of Medicine Dr. Howe is Professor of Surgery at the University of Iowa. He trained in General Surgery at Barnes Hospital/Washington University, which included a T32 Surgical Oncology research fellowship where he was a member of the group that found the gene responsible for Multiple Endocrine Neoplasia type 2 by positional cloning. He completed a clinical fellowship in Surgical Oncology at Memorial Sloan-Kettering Cancer Center, then began his career at the University of Iowa in 1996. Here he has specialized in gastrointestinal cancer and endocrine surgery, and his research has concentrated on genetic studies of cancer. His laboratory discovered a gene that causes the inherited colorectal cancer syndrome Juvenile Polyposis in 1998, and in 2001 identified a second predisposition gene. Dr. Howe has written over 170 peer-reviewed papers, one book, and over 50 book chapters. He has directed the Division of Surgical Oncology and Endocrine Surgery since 2002, and his clinical practice and research has focused on small bowel and pancreatic neuroendocrine tumors (NETs) and their metastases. Dr. Howe served as President of the North American Neuroendocrine Tumor Society from 2018-20 and the Society of Surgical Oncology from 2020-21. Clinically he is known for his work on cytoreduction of NET liver metastases and guidelines for the surgical management of small bowel and pancreatic NETs. Dr. Howe has directed a funded laboratory over his career, been chair of an NIH Study Section, and his current research focuses on gene expression and drug sensitivity in NETs. SURGERY: GI NETS ALEXANDRA GANGI, MD Surgical Oncologist Cedars-Sinai Medical Center Dr. Alexandra Gangi is a board-certified surgical oncologist at Cedars-Sinai Medical Center in Los Angeles. Dr. Gangi completed a general surgical residency at Cedars-Sinai and completed her surgical oncology fellowship at the H. Lee Moffitt Cancer Center in Tampa, Florida. She currently serves as the director of the Gastrointestinal Tumor and Cancer Regional Therapies Programs with specialization in Pancreatic and GI Neuroendocrine tumors, Metastatic colorectal cancer, and Peritoneal Surface Malignancies. Her research focuses on understanding GEPNET heterogeneity between and within tumors subtypes and mechanisms of chemotherapy induced liver injury. SURGERY: PNETS CALLISIA CLARKE, MD Chief of Surgical Oncology Medical College of Wisconsin Dr. Callisia Clarke completed her medical degree at the University of Cincinnati College of Medicine where she was elected to the Alpha Omega Alpha Honors Society. She completed a general surgery residency at the University of Cincinnati Medical Center in Cincinnati, Ohio in 2013 and a fellowship in Complex General Surgical Oncology at The University of Texas MD Anderson Cancer Center in 2016. She joined the faculty at the Medical College of Wisconsin in 2016 and is an Associate Professor of Surgery, and Chief of the Division of Surgical Oncology. Her research efforts are centered on epigenetic regulation of pancreatic neuroendocrine tumors and Diversity, Equity, and Inclusion in academic surgery. She holds several leadership positions in national organizations. She was recently elected the President-Elect of the Association for Academic Surgery, the first Black Woman to hold this office. And serves in other leadership roles in the Society of Surgical Oncology and the American Board of Surgery. SURGERY: LIVER NETS JONATHAN HERNANDEZ Chief of Surgical Oncology National Cancer Institute Dr. Hernandez graduated from medical school with honors from the University of Florida, and completed general surgery training at the University of South Florida. During his residency, Dr. Hernandez spent two years at the Moffitt Cancer Center and Research Institute interrogating molecular diagnostics for liver metastases and miRNA-mediated mechanisms of metastatic spread with the support of NIH funding. Following residency, Dr. Hernandez completed fellowship training in both surgical oncology and hepatopancreatobiliary surgery at Memorial Sloan Kettering Cancer Center. During his fellowships, Dr. Hernandez spent an additional two years in dedicated basic research studying metastatic colonization as a scholar in the Cell Biology Program of the Sloan Kettering Institute supported by NIH funding and a grant from America’s HepatoPancreatoBiliary Association. Dr. Hernandez was also a visiting investigator in the Cell and Developmental Biology Department of Weill Medical College of Cornell University studying metastatic niche evolution with funding support from the Conquer Cancer Foundation of the American Society of Clinical Oncology. Dr. Hernandez has authored over 150 peer-reviewed publications and has contributed book chapters in numerous authoritative surgical textbooks. Dr. Jonathan Hernandez is a surgical oncologist/HPB surgeon, chief of the surgical oncology section (Surgical Oncology Program/NCI/NIH), an Associate Professor of Surgery (Uniformed Services University of the Health Sciences), and a Clinical Professor of Surgery (George Washington University). He specializes in the treatment of metastatic and primary tumors of the liver, bile ducts and pancreas, as well as in the surgical management of complex abdominal tumors. Dr. Hernandez’s research efforts focus on implementation of ex-vivo human tumor systems that allow his lab to fully characterize tumors from the operating room and evaluate new therapies in an unfettered platform. The Hernandez lab utilizes these human tumor systems to 1) develop combination therapies for recalcitrant tumors, 2) delineate and target uncharacterized signaling axes for therapeutic gain in patients with cholangiocarcinoma, and 3) elucidate the mechanisms through which tumor cells coopt the microenvironment of distant organs to form life-threatening metastases. SURGERY: UNDERSTANDING CARCINOID CRISIS JULIE HALLET, MD, MSc, FRCSC, FSSO Associate Professor of Surgery Sunnybrook Health Sciences Center Dr. Hallet is an Associate Professor of Surgery at the University of Toronto and a Surgical Oncologist with a clinical practice devoted to hepato-biliary, pancreatic and upper gastrointestinal malignancies at the Odette Cancer Centre - Sunnybrook Health Sciences Centre. Her practice further focuses on neuroendocrine tumors as part of the Susan Leslie Multidisciplinary Clinic for Neuroendocrine Tumors, as well as minimally invasive therapies for cancer treatment. She completed general surgery residency and MSc in clinical epidemiology at Université Laval in Québec City, followed by a Surgical Oncology and hepato-pancreatico-biliary clinical fellowship at the University of Toronto, and additional training in advanced minimally invasive surgery at the Institut de recherche contre les cancers de l’appareil digestif (IRCAD) in Strasbourg, France. Dr. Hallet holds leadership roles in National and International societies. Among those roles, she serves as the Vice-Chair of the Hepato-Pancreatico-Biliary Disease Site Group of the Society of Surgical Oncology, the Chair of the Early Career Group the International Hepato-Pancreatico-Biliary Association, and a member of the Guidelines Committee of the North American Neuroendocrine Tumors Society, as well as on the executive committees of the Canadian Society of Surgical Oncology and the Canadian Hepato-Pancreato-Biliary Association. She is a founding member of the Society of Surgical Ergonomics for which she also chairs the Research and Applied Ergonomics Committee. She also is Associate Section Editor for the Annals of Surgical Oncology, and is part of the Editorial Board of HPB, the World Journal of Surgery, and the British Journal of Surgery. Dr. Hallet’s research focuses on health services research to examine processes of care and outcomes in oncology, with a focus on patient-centred and patient-reported outcomes. To support her research, she has received over $10 millions in operating grants, including from the Canadian Institutes of Health Research and the Ontario Institute of Cancer Research. Dr. Hallet has over 200 peer-reviewed publications, including high-impact papers in JAMA Surgery, JAMA Oncology, the Journal of the NCCN, and Annals of Surgery. THE ROLE OF NEOADJUVANT/ADJUVANT TREATMENT: DO I START SSA OR CHEMO BEFORE OR AFTER SURGERY? HELOISA SOARES, MD Medical Oncologist Associate Professor Huntsman Cancer Institute, University of Utah Dr. Heloisa Soares is a medical oncologist with a focus in GI and neuroendocrine cancers. She is an associate professor at the Huntsman Cancer Institute (HCI) at University of Utah. Dr. Soares received her medical degree at Faculdade de Medicine do ABC in Brazil, where she was born. She completed her residency training at the Mount Sinai Medical Center of Florida and her hematology-oncology fellowship training and PhD in molecular biology at UCLA. Dr. Soares has neuroendocrine tumors and gastrointestinal (GI) cancers as the major focus of her research and clinical activities. She serves as the Medical Director for the Clinical Trials Office as well as the co-physician leader in the GI Clinical Trials Research Group at HCI. In 2019, she was elected as a member of the board of directors for The North American Neuroendocrine Tumor Society (NANETS). Additionally, she is a member of the NCI NET taskforce and member of SWOG and NRG cooperative groups. She is also a panel member for the Neuroendocrine and Adrenal Tumors NCCN Clinical Practice Guidelines in Oncology. MEDICAL 101 FOR NETS SANDY KOTIAH, MD Director, The Neuroendocrine Tumor Center Mercy Medical Center Sandy D. Kotiah, M.D., a Board Certified medical oncologist, serves as the Director of The Neuroendocrine Tumor Center at Mercy and is a member of Medical Oncology and Hematology at Mercy in Baltimore, Maryland. Dr. Kotiah leads a multidisciplinary team of specialty doctors focused on providing some of the best treatment options for rare neuroendocrine diseases. Dr. Kotiah’s compassionate and caring nature as well as her exceptional clinical knowledge and dedication to searching for answers to complicated cancer diagnoses makes her a sought-after Medical Oncologist and Hematologist in the Baltimore region. SYSTEMIC TREATMENTS - WHAT, WHEN & WHY OF MEDICAL THERAPIES (11:40 AM) WHAT'S NEW WITH PRRT: CLINICAL TRIALS (2:20 PM) AMAN CHAUHAN, MD Medical Oncologist University of Miami Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer Institute (NCI) that focused on designing clinical trials and clinical research projects. His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is national principal investigator on several investigator initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee. Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society. NUTS & BOLTS OF CLINICAL TRIALS JAYDIRA DEL RIVERO, MD Endocrinologist and Oncologist National Cancer Institute Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. PRRT: WHAT PATIENTS NEED TO KNOW ERIK MITTRA, MD, PhD Radiologist, Nuclear Medicine Oregon Health & Science University Dr. Mittra is a Professor of Diagnostic Radiology at Oregon Health & Science University (OHSU) where he serves as Chief of the Molecular Imaging and Therapy Section and Director of the Targeted Radiopharmaceutical Therapy Program. Dr. Mittra received his medical and graduate degrees through the MD/PhD program at Stony Brook University. His post-graduate training included an internship at Stony Brook University, followed by a residency and fellowship in Nuclear Medicine at Stanford University where he was faculty for many years before moving to OHSU. Dr. Mittra is interested in all aspects of nuclear medicine with a focus on targeted radiopharmaceutical therapies. His research interests are focused on the translation of novel radioisotopes for imaging and therapy. He is involved with the Society of Nuclear Medicine and Molecular Imaging (SNMMI), and the North American Neuroendocrine Tumor Society (NANETS), among others. PRRT-RELATED TOXICITIES THOR HALFDANARSON, MD Professor of Oncology Mayo Clinic College of Medicine and Science Thor Halfdanarson, MD Mayo Clinic Dr. Halfdanarson is a professor of Oncology at the Mayo Clinic College of Medicine and Science and a consultant in Medical Oncology at the Mayo Clinic. He specializes in GI oncology with a focus on NETs and cancers of unknown primary, serves as the Associate Medical Director of the Cancer Clinical Trials Office at the Mayo Clinic Comprehensive Cancer Center and is the co-chair of the Pancreatic/Neuroendocrine Tumor Board. Dr. Halfdanarson is a member of the NCCN guidelines panel for NETs, the Co-Chair of the NET Group at Alliance for Clinical Trials in Oncology and the current Vice President of NANETS.ar medicine and molecular imaging. He is the inaugural chair of the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) Patient Advocacy Advisory Board, Board Member and Treasure of the Neuroendocrine Tumor Research Foundation (NETRF), a member of The Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF) Board, and president of NorCal CarciNET Community, one of the largest NET patient communities in the United States. He is currently the sole patient rights advocate for the Nuclear Regulatory Commission’s Advisory Committee for the Medical Use of Isotopes (ACMUI).